# Sofinnova Crossover I (€445M final close, 2021)

> Predecessor late-stage healthcare crossover vehicle of Sofinnova Partners. The GP announced a €445M FINAL close on March 3, 2021, after an earlier €275M initial close in April 2018. Investments included later-stage European biopharma and medtech companies seeking scale-up capital. The fund's notable GP-cited companies include Amolyt Pharma, Abivax, LimFlow and Calliditas. No 2026 incremental raise is implied.

## Profile

- **Stage-based planning range:** $100K–$1M
- **Check-size evidence basis:** estimated
- **Founded:** N/A
- **Headquarters:** Paris, France; Europe plus selective international markets
- **AUM:** N/A
- **Rounds they lead:** N/A
- **Rounds they invest:** N/A
- **Last verified:** 2026-11-16

## Links

- [Website](https://sofinnovapartners.com)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 16, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/fund/sofinnova-crossover-i
